Loi S, Michiels S, Salgado R, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol. 2014;25(8):1544–50. https://doi.org/10.1093/annonc/mdu112[publishedOnlineFirst:20140307].

Article  CAS  PubMed  Google Scholar 

Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013;31(7):860–7. https://doi.org/10.1200/JCO.2011.41.0902[publishedOnlineFirst:20130122].

Article  CAS  PubMed  Google Scholar 

Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19(1):40–50. https://doi.org/10.1016/s1470-2045(17)30904-x[publishedOnlineFirst:2017/12/14].

Article  PubMed  Google Scholar 

Adams S, Gray RJ, Demaria S, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32(27):2959.

Article  PubMed  PubMed Central  Google Scholar 

Loi S, Drubay D, Adams S, et al. Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers. J Clin Oncol. 2019;37(7):559–69. https://doi.org/10.1200/jco.18.01010[publishedOnlineFirst:2019/01/17].

Article  PubMed  PubMed Central  Google Scholar 

Leon-Ferre RA, Polley M-Y, Liu H, et al. Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer. Breast Cancer Res Treat. 2018;167(1):89–99.

Article  CAS  PubMed  Google Scholar 

Leon-Ferre RA, Jonas SF, Salgado R, et al. Tumor-infiltrating lymphocytes in triple-negative breast cancer. JAMA. 2024;331(13):1135–44.

Article  CAS  PubMed  Google Scholar 

Krieg C, Nowicka M, Guglietta S, et al. High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy. Nat Med. 2018;24(2):144–53.

Article  CAS  PubMed  Google Scholar 

Wistuba-Hamprecht K, Martens A, Weide B, et al. Establishing high dimensional immune signatures from peripheral blood via mass cytometry in a discovery cohort of stage IV melanoma patients. J Immunol. 2017;198(2):927–36.

Article  CAS  PubMed  Google Scholar 

Axelrod ML, Nixon MJ, Gonzalez-Ericsson PI, et al. Changes in peripheral and local tumor immunity after neoadjuvant chemotherapy reshape clinical outcomes in patients with breast cancerimmunologic changes with chemotherapy in TNBC. Clin Cancer Res. 2020;26(21):5668–81.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huebner H, Rübner M, Schneeweiss A, et al. RNA expression levels from peripheral immune cells, a minimally invasive liquid biopsy source to predict response to therapy, survival and immune-related adverse events in patients with triple negative breast cancer enrolled in the GeparNuevo trial. American Society of Clinical Oncology; 2023.

Book  Google Scholar 

Spitzer MH, Nolan GP. Mass cytometry: single cells, many features. Cell. 2016;165(4):780–91.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goetz MP, Kalari KR, Suman VJ, et al. Tumor sequencing and patient-derived xenografts in the neoadjuvant treatment of breast cancer. JNCI J Natl Cancer Inst. 2017;109(7):djw306.

Article  PubMed  Google Scholar 

Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22(8):1736–47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Symmans WF, Wei C, Gould R, et al. Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype. J Clin Oncol. 2017;35(10):1049.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yau C, Osdoit M, van der Noordaa M, et al. Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients. Lancet Oncol. 2022;23(1):149–60.

Article  CAS  PubMed  Google Scholar 

Rybakowska P, Van Gassen S, Quintelier K, et al. Data processing workflow for large-scale immune monitoring studies by mass cytometry. Comput Struct Biotechnol J. 2021;19:3160–75.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sahaf B, Pichavant M, Lee BH, et al. Immune profiling mass cytometry assay harmonization: multicenter experience from CIMAC-CIDC. Clin Cancer Res. 2021;27(18):5062–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Finck R, Simonds EF, Jager A, et al. Normalization of mass cytometry data with bead standards. Cytometry A. 2013;83(5):483–94. https://doi.org/10.1002/cyto.a.22271[publishedOnlineFirst:20130319].

Article  PubMed  PubMed Central  Google Scholar 

Bagwell CB, Inokuma M, Hunsberger B, et al. Automated data cleanup for mass cytometry. Cytometry A. 2020;97(2):184–98.

Article  CAS  PubMed  Google Scholar 

Van Gassen S, Callebaut B, Van Helden MJ, et al. FlowSOM: using self-organizing maps for visualization and interpretation of cytometry data. Cytometry A. 2015;87(7):636–45.

Article  PubMed  Google Scholar 

McInnes L, Healy J, Melville J. Umap: uniform manifold approximation and projection for dimension reduction. arXiv preprint https://arxiv.org/abs/1802.03426 (2018).

Leon-Ferre RA, Jonas SF, Salgado R, et al. Abstract PD9-05: stromal tumor-infiltrating lymphocytes identify early-stage triple-negative breast cancer patients with favorable outcomes at 10-year follow-up in the absence of systemic therapy: a pooled analysis of 1835 patients. Cancer Res. 2023;83(5):PD9-05.

Article  Google Scholar 

Verghese G, Li M, Liu F, et al. Multiscale deep learning framework captures systemic immune features in lymph nodes predictive of triple negative breast cancer outcome in large-scale studies. J Pathol. 2023;260(4):376–89.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu F, Hardiman T, Wu K, et al. Systemic immune reaction in axillary lymph nodes adds to tumor-infiltrating lymphocytes in triple-negative breast cancer prognostication. NPJ Breast Cancer. 2021;7(1):86.

Article  PubMed  PubMed Central  Google Scholar 

Engblom C, Pfirschke C, Pittet MJ. The role of myeloid cells in cancer therapies. Nat Rev Cancer. 2016;16(7):447–62.

Article  CAS  PubMed  Google Scholar 

Condamine T, Mastio J, Gabrilovich DI. Transcriptional regulation of myeloid-derived suppressor cells. J Leucoc Biol. 2015;98(6):913–22.

Article  CAS  Google Scholar 

Gubin MM, Esaulova E, Ward JP, et al. High-dimensional analysis delineates myeloid and lymphoid compartment remodeling during successful immune-checkpoint cancer therapy. Cell. 2018;175(4):1014–30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhu Y, Herndon JM, Sojka DK, et al. Tissue-resident macrophages in pancreatic ductal adenocarcinoma originate from embryonic hematopoiesis and promote tumor progression. Immunity. 2017;47(2):323–38.

Article  CAS  PubMed  PubMed Central  Google Scholar